Nurix Therapeutics, Inc. 4

Chief Scientific Officer Gwenn Hansen exercised 1,452 options and sold 1,452 shares of Nurix Therapeutics, Inc. common stock on 2026-09-01 under a Rule 10b5-1 plan.

On 2026-09-01, Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen exercised 1,452 employee stock options at an exercise price of $1.86 per share, acquiring an equal number of common shares, and then sold all 1,452 shares on the same day at $25.47 per share under a pre-arranged Rule 10b5-1 trading plan. The option exercise itself did not involve an open-market cash outlay beyond the strike price, and the paired sale effectively monetized the option gain while slightly reducing her directly held common stock position from 118,679 to 117,227 shares. Following the transactions, Hansen beneficially owned 117,227 shares of common stock, which, using the reported sale price as a proxy for market price, represent an equity stake worth approximately $2.98 million.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817160-26-000019

Alert Tier

5